SV

Street Verdict

Analyst Scorecard

POLYMED · NSE

Poly Medicure Limited

₹1,635.7

-2.09% (-₹34.9)

Prev. close

₹1,670.6

Volume

37,535

Delivery %

46.3%

As of

20 Nov 2026

Price history

₹1,635.7-₹149 (-8.35%) · 3M
18 Aug 2026 → 20 Nov 2026
1,4501,5001,5501,6001,6501,7001,75018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Fundamentals

About Poly Medicure Limited

Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, including I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous catheters, and huber needle; dialysis and renal care products, comprising peritoneal dialysis set, haemocent, standard and safety fistula needle, dialyzer, bloodlines and dialysis system. It also provides cardiology products PTFE wire, inflation device, Y-connector, manifold, introducer, IV Cannula, hydrophilic wire, guiding catheter, drug eluting stent, PTCA balloon dilation catheter, diagnostic catheter, and electrocardiograph electrodes; vaccular access products; oncology products; diagnostics products, including blood collection tubes, safety blood collection set, blood collection needles, and standard needle holder. In addition, the company offers transfusion system products, including blood bags, blood administration set, and others; anesthesia and respiratory care products, comprising variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, aerosol therapy masks, ventilator circuits, suction catheters, spinal needle, polyciser, oxygen catheter, nebulizer compressor system, twin bore nasal oxygen cannula mucus extractor, HME filter, oro-pharyngeal airways, endotracheal tubes, catheter mount, and brain circuit; urology products, including urine collection bags, leg bag set, irrigation sets, and foley balloon and urine drainage catheters; wound drainage; and gastroenterology products. The company was incorporated in 1995 and is based in New Delhi, India.

Details

Sector

Healthcare

Industry

Medical Instruments & Supplies

CEO

Mr. Himanshu Baid

Headquarters

New Delhi

Employees

2,614

Key stats

Market cap

₹16,084.04 Cr

P/E ratio (TTM)

51.1

Dividend yield

0.23%

EPS (TTM)

₹31.06

Beta (1Y · daily vs NIFTY 50)

0.91

Beta (5Y · monthly vs NIFTY 50)

0.91

Shares float

3.63 Cr

EPS · quarter ended Jun 2026

₹8.48

Financial Performance

01 · Financials

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹0%10%20%30%FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

010203040₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

01234₹-200%0%200%400%27 Feb 2016 Sept 2116 Sept 2221 Sept 2319 Sept 2418 Sept 2528 Aug 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

0%20%40%60%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹0×0.25×0.5×0.75×1×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-200 Cr0 Cr200 Cr400 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss — as filed

Annual

Line itemFY21FY22FY23FY24FY25
₹804.88 Cr₹960.97 Cr₹1,151.42 Cr₹1,434.54 Cr₹1,758.96 Cr
₹628.14 Cr₹768.17 Cr₹915.85 Cr₹1,092.80 Cr₹1,311.62 Cr
Profit before tax, and share of net profit from associates
₹176.74 Cr₹192.80 Cr₹235.56 Cr₹341.74 Cr₹447.34 Cr
Share of profit from associates
₹3.31 Cr₹2.45 Cr₹1.93 Cr₹2.53 Cr₹5.18 Cr
Profit before tax
₹180.05 Cr₹195.24 Cr₹237.49 Cr₹344.27 Cr₹452.52 Cr
₹44.18 Cr₹48.74 Cr₹58.21 Cr₹86.01 Cr₹113.96 Cr
Profit after tax
₹135.87 Cr₹146.51 Cr₹179.28 Cr₹258.26 Cr₹338.56 Cr
Acturial gains/(losses) of defined benefit plan
₹13.98 L————
Re-measurement gains/(losses) of defined benefit plan
—₹31.69 L₹19.80 L₹-1.13 Cr₹-2.07 Cr
Tax impacts on above
₹-3.52 L₹-7.98 L₹-4.98 L₹28.43 L₹52.04 L
₹135.98 Cr₹146.43 Cr₹179.69 Cr₹257.38 Cr₹337.20 Cr
Equity holders of the parent
₹135.87 Cr₹146.51 Cr₹179.28 Cr₹258.26 Cr₹338.56 Cr
Equity holders of the parent
₹135.98 Cr₹146.43 Cr₹179.69 Cr₹257.38 Cr₹337.20 Cr
Basic
15.2515.2818.6926.9234.13
Diluted
15.2415.2718.6726.9034.11
Basic
₹8.91 Cr₹9.59 Cr₹9.59 Cr₹9.59 Cr₹9.92 Cr
Diluted
₹8.92 Cr₹9.60 Cr₹9.60 Cr₹9.60 Cr₹9.92 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

09 · Balance Sheet — as filed

Annual

Line itemFY21FY22FY23FY24FY25
₹519.62 Cr₹593.40 Cr₹770.52 Cr₹1,017.07 Cr₹1,275.46 Cr
₹1,223.73 Cr₹1,376.83 Cr₹1,577.21 Cr₹1,858.67 Cr₹3,192.45 Cr
₹965.57 Cr₹1,087.48 Cr₹1,241.63 Cr₹1,470.05 Cr₹2,765.66 Cr
₹86.76 Cr₹62.68 Cr₹42.28 Cr₹37.40 Cr₹56.63 Cr
₹1,223.73 Cr₹1,376.83 Cr₹1,577.21 Cr₹1,858.67 Cr₹3,192.45 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

10 · Cash Flow Statement — as filed

Annual

Line itemFY21FY22FY23FY24FY25
Profit before tax and exceptional items
₹180.05 Cr₹195.24 Cr₹237.49 Cr₹344.27 Cr₹452.52 Cr
Depreciation and amortisation (Note 31)
₹47.52 Cr₹53.95 Cr₹57.17 Cr₹63.93 Cr₹83.18 Cr
Share in Income of Associates
₹-3.31 Cr₹-2.45 Cr₹-1.93 Cr₹-2.53 Cr₹-5.18 Cr
Interest expense
₹8.51 Cr₹4.25 Cr₹8.84 Cr₹11.30 Cr₹12.00 Cr
Interest income
₹-3.09 Cr₹-1.99 Cr₹-5.86 Cr₹-12.95 Cr₹-13.03 Cr
Loss/(profit) on sale of Property plant and equipment & investment properties (net)
₹-72,000₹-53.05 L₹-10.03 L₹-62.28 L₹-12.03 L
Debts/advances written off
₹17.99 L₹66.06 L₹14.22 L₹1.18 Cr₹33.21 L
Provision for doubtful debts and advances
₹29.96 L₹3.08 L₹59.39 L₹1.13 Cr₹3.18 Cr
Credit balances no longer required, written back
₹-1.67 L₹-36.89 L₹-21.23 L₹-51.36 L₹-95.07 L
Deferred employee compensation expenses (net)
₹64.73 L₹93.10 L₹1.93 Cr₹2.11 Cr₹1.22 Cr
Unrealised foreign exchange (gain) /loss
₹10.29 L₹-2.88 Cr₹-85.74 L₹-1.81 Cr₹-1.40 Cr
Other Comprehensive Income
₹13.98 L₹31.69 L———
Ind As Adjustment for Unrealised Gain on Mutual Fund
₹-3.51 Cr————
Ind As Adjustment on Govt. Grant & Subsidy
₹-1.09 Cr————
Ind As Adjustment for Interest Income on Financial Assets
₹-28.16 L————
Ind As Adjustment on Forward Contracts (Net)
₹-2.16 Cr————
Ind As Adjustment for Deferred Processing fees
₹31.17 L————
Ind As Adjustment for Interest on Security Deposit against Rent
₹3.88 L————
Other adjustments including minority
₹20.31 L————
Unrealised (Gain)/Loss on Mutual Fund
——₹4.01 Cr₹-20.95 Cr₹-37.73 Cr
Ind As and other adjustments
—₹-12.86 Cr₹-2.83 Cr₹3.51 Cr₹6.86 Cr
Operating profit before working capital changes
₹224.54 Cr₹234.32 Cr₹298.38 Cr₹381.04 Cr₹487.15 Cr
Decrease/(increase) in inventories
₹-14.39 Cr₹-41.88 Cr₹-40.29 Cr₹-12.38 Cr₹-64.54 Cr
Decrease/ (increase) in sundry debtors
₹-33.23 Cr₹-50.74 Cr₹-28.80 Cr₹-36.69 Cr₹-83.75 Cr
Decrease/(Increase) in financial assets
₹14.61 L₹64.31 L₹-13.51 L₹-7.32 Cr₹3.27 Cr
Decrease/(Increase) in other assets
₹-10.42 Cr₹-8.67 Cr₹-99.10 L₹2.60 Cr₹-13.77 Cr
Increase/ (decrease) in trade payables
₹5.95 L₹24.70 Cr₹3.77 Cr₹3.76 Cr₹-7.28 Cr
Increase/ (decrease) in other financial liabilities
₹1.06 Cr₹1.18 Cr₹5.93 Cr₹13.58 Cr₹9.78 Cr
Increase/ (decrease) in other liabilities
₹-3.90 Cr₹10.75 Cr₹9.77 Cr₹-4.46 Cr₹59.36 L
Increase/ (decrease) in provisions
₹-51.45 L₹62.01 L₹1.28 Cr₹23.95 L₹1.39 Cr
₹118.73 Cr₹123.47 Cr₹191.05 Cr₹266.08 Cr₹240.42 Cr
Cash generated from operations
₹163.35 Cr₹170.93 Cr₹248.92 Cr₹340.38 Cr₹332.83 Cr
Direct taxes paid (net of refunds)
₹-44.62 Cr₹-47.46 Cr₹-57.87 Cr₹-74.30 Cr₹-92.41 Cr
₹-435.58 Cr₹-85.33 Cr₹-179.24 Cr₹-240.94 Cr₹-1,194.28 Cr
₹316.95 Cr₹-35.34 Cr₹-12.51 Cr₹-20.15 Cr₹950.51 Cr
₹4.95 Cr₹7.76 Cr—₹12.05 Cr₹8.70 Cr
Net increase in cash and cash equivalents (A+B+C)
₹9.72 L₹2.80 Cr—₹4.99 Cr₹-3.35 Cr
Cash and cash equivalents at the beginning of the year
₹4.86 Cr₹4.95 Cr—₹7.06 Cr₹12.05 Cr
₹4.95 Cr₹7.76 Cr†—₹12.05 Cr₹8.70 Cr
Cash and cash equivalents at the end of the year as per above
₹4.95 Cr†₹7.76 Cr†—₹12.05 Cr₹8.70 Cr
———₹153.95 Cr₹164.31 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

† Computed, not printed: that year’s report leaves this figure out, but the lines it does print fix it exactly (hover for the sum). The same relationship holds in every year where all of its lines are printed.

All years: consolidated statements.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21Mar 22Jun 22Sep 22–Dec 22(2Q)Mar 23–Jun 23(2Q)Sep 23–Dec 23(2Q)Mar 24Jun 24Aug 24–Sep 24(2Q)Dec 24–Jun 25(3Q)Sep 25–Jun 26(4Q)
Promoter44.77%44.76%44.66%53.34%53.33%53.31%53.16%53.15%66.03%62.56%62.44%62.42%
Public55.23%55.24%55.34%46.66%46.67%46.69%46.84%46.85%33.97%37.44%37.56%37.58%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Poly Medicure Limited₹14,971.09 Cr₹1,496.247.64.8210.4%0.11+12.4%-21.9%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

POLYMED

Poly Medicure Q2 FY27: Sales Up 30.8% to ₹581 Cr, a Failed Project Books a Gain, and Dialyzers Told to Go...

Howl.Link · 8 days ago

POLYMED

Poly Medicure looks to double revenue by FY30, led by organic growth

CNBC TV18 · 10 days ago